<DOC>
	<DOCNO>NCT00303186</DOCNO>
	<brief_summary>The purpose study conduct economic analysis cost conventional therapy compare biologic therapy direct/indirect cost disease management patient refractory psoriatic arthritis ( PsA ) . Primary outcome qualify economic burden refractory PsA care . The secondary outcome assess efficacy , safety , cost effectiveness different therapy .</brief_summary>
	<brief_title>Study Evaluating Cost Treatments Refractory Psoriatic Arthritis Conventional Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Eighteen year age old Inflammatory arthropathy associate psoriasis meet ACR criterion PsA Patients diagnosis active progressive PsA failure conventional treatment Significant concurrent medical disease include cancer history cancer , uncontrolled congestive heart failure , myocardial infarction within 12 month clinically significant cardiovascular disease , immunodeficiency syndrome concomitant infectious disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>